IRIS
CECCHERINI SILBERSTEIN, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 74.336
AS - Asia 11.922
EU - Europa 9.643
SA - Sud America 1.859
Continente sconosciuto - Info sul continente non disponibili 1.356
AF - Africa 274
OC - Oceania 37
Totale 99.427
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 73.701
SG - Singapore 5.735
IT - Italia 2.015
CN - Cina 2.004
BR - Brasile 1.453
RU - Federazione Russa 1.330
DE - Germania 1.126
HK - Hong Kong 1.017
VN - Vietnam 923
SE - Svezia 817
UA - Ucraina 816
IE - Irlanda 800
BD - Bangladesh 712
FR - Francia 593
GB - Regno Unito 525
FI - Finlandia 509
PL - Polonia 454
KR - Corea 432
JP - Giappone 314
CA - Canada 310
IN - India 171
NL - Olanda 151
AR - Argentina 133
ID - Indonesia 126
MX - Messico 116
AT - Austria 110
ES - Italia 105
ZA - Sudafrica 74
CO - Colombia 70
TR - Turchia 69
BE - Belgio 64
EC - Ecuador 64
PH - Filippine 50
CZ - Repubblica Ceca 49
IQ - Iraq 48
JM - Giamaica 47
PK - Pakistan 43
UZ - Uzbekistan 35
VE - Venezuela 35
CL - Cile 33
MY - Malesia 30
CR - Costa Rica 29
AU - Australia 28
CH - Svizzera 28
ET - Etiopia 27
HN - Honduras 27
PY - Paraguay 27
KE - Kenya 24
MA - Marocco 23
AE - Emirati Arabi Uniti 22
NG - Nigeria 21
PE - Perù 20
JO - Giordania 19
LT - Lituania 19
DZ - Algeria 18
SA - Arabia Saudita 18
CM - Camerun 17
RO - Romania 17
EG - Egitto 16
EU - Europa 16
GT - Guatemala 16
IL - Israele 16
IR - Iran 16
KZ - Kazakistan 15
TH - Thailandia 14
DO - Repubblica Dominicana 12
GR - Grecia 12
NP - Nepal 12
PT - Portogallo 12
TT - Trinidad e Tobago 12
TW - Taiwan 12
UY - Uruguay 12
EE - Estonia 11
NI - Nicaragua 11
TN - Tunisia 11
DK - Danimarca 10
KG - Kirghizistan 10
SV - El Salvador 10
AL - Albania 9
BG - Bulgaria 9
NZ - Nuova Zelanda 9
PR - Porto Rico 9
AZ - Azerbaigian 8
BO - Bolivia 8
AO - Angola 7
BB - Barbados 7
HR - Croazia 7
HU - Ungheria 7
PA - Panama 7
SC - Seychelles 7
XK - ???statistics.table.value.countryCode.XK??? 7
OM - Oman 6
PS - Palestinian Territory 6
RS - Serbia 6
CI - Costa d'Avorio 5
CY - Cipro 5
GD - Grenada 5
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
Totale 97.998
Salva come PNG Salva come JPEG
Città #
Woodbridge 17.829
Wilmington 17.461
Houston 14.259
Singapore 3.088
Ashburn 2.304
Fairfield 2.208
San Jose 1.839
Chandler 1.376
Ann Arbor 1.360
Hong Kong 991
Seattle 902
Council Bluffs 860
Beijing 822
Cambridge 719
Dublin 695
Jacksonville 667
Rome 609
Santa Clara 555
Medford 494
New York 473
Los Angeles 440
Dearborn 368
Kraków 359
The Dalles 339
Helsinki 297
Ho Chi Minh City 295
Tokyo 280
Hanoi 232
Buffalo 231
Lawrence 231
Moscow 224
Milan 218
Dallas 168
Munich 165
San Diego 159
Denver 158
São Paulo 154
Lauterbourg 133
Chicago 125
Menlo Park 125
Nuremberg 118
Orem 117
Phoenix 106
London 105
Mülheim 103
Boardman 100
Atlanta 87
Jakarta 86
Brooklyn 80
Montreal 70
Zhengzhou 70
Toronto 69
Frankfurt am Main 65
San Francisco 65
North Bergen 64
Brussels 61
Creede 59
Redondo Beach 56
Vienna 56
Warsaw 55
Naples 54
New Orleans 50
Johannesburg 47
Chennai 46
Columbus 45
Rio de Janeiro 45
Shanghai 44
Mexico City 43
Palo Alto 43
Falls Church 42
Guangzhou 42
Lappeenranta 42
Redwood City 42
Amsterdam 41
Poplar 38
Boston 37
Stockholm 36
Cedarhurst 35
Nanjing 35
Colorado Springs 34
Haiphong 34
Mountain View 34
Da Nang 33
Verona 32
Belo Horizonte 31
Bogotá 31
Brasília 31
Manchester 30
University Park 30
Washington 30
Brno 29
Dong Ket 29
Norwalk 29
Philadelphia 29
Kingston 28
Bari 27
Charlotte 27
Kunming 27
Miami 26
Madrid 25
Totale 77.237
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 606
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 593
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 580
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 561
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 555
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 547
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 545
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 544
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 537
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 533
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 529
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 527
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 524
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 522
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 519
Understanding HIV compartments and reservoirs 513
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 510
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 505
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 505
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 502
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 501
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 500
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 499
Novel drug resistance mutations in HIV: Recognition and clinical relevance 496
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 492
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 490
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 488
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 487
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 484
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 484
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 483
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 481
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 480
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 478
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 477
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 476
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 476
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 475
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors 473
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 472
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 472
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 469
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 468
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 466
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 466
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort 464
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 463
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 462
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 462
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 460
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study 459
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 458
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 457
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 457
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 457
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 457
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors 456
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 456
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 455
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 455
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 455
Gene transfer in astrocytes: comparison between different delivering methods and expression of the HIV-1 protein Nef 454
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 454
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 453
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 453
The use of human immunodeficiency virus resistance tests in clinical practice 452
Dynamics of NRTI resistance mutations during therapy interruption 450
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir 450
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 449
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 449
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 448
The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A 446
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 446
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 444
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 441
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 440
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 439
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 438
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs 437
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 437
Molecular diversity of HIV in Albania 437
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 437
Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients 436
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 436
HIV-Infected Late Presenter Patients 435
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 434
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 434
Resistance to novel drug classes 433
HIV-2 A-subtype gp125(C2-V3-C3) mutations and their association with CCR5 and CXCR4 tropism. 433
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 433
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 432
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 430
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 430
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 430
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 428
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 428
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 427
Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages 427
From current status to optimization of HCV treatment: Recommendations from an expert panel 427
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 427
Totale 47.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 262.823
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 262.823
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.445 0 0 0 148 120 230 183 126 564 242 150 682
2022/20233.815 419 295 194 447 351 793 270 354 313 43 240 96
2023/20241.502 226 44 90 58 120 255 71 61 57 207 34 279
2024/20258.670 280 1.700 929 481 251 544 1.029 420 791 514 863 868
2025/202615.821 1.261 586 1.441 1.427 1.411 647 1.995 1.985 1.730 1.386 1.000 952
2026/20275.548 929 794 2.694 1.131 0 0 0 0 0 0 0 0
Totale 99.427